Galderma Group AG risk profile
39 Normal where most of the sector sits
Measured 1 September 2026 from PY30's filed statements. Recomputed nightly.
39 (Normal), driven by Competitive position at 52, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 39 | Normal | Stable | Average daily turnover — $915 |
| Operating pressure | 31 | Normal | Easing | Costs outgrowing revenue — -2.0 percentage points |
| Cash conversion | 14 | Contained | Easing | Capital spending against operating cash — 0.13x |
| Leverage and coverage | 37 | Normal | Easing | Interest cover — 6.49x |
| Competitive position | 52 | Elevated | Stable | Operating-margin gap against peers — +3.2 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Galderma Group AG